Sona Kontsekova PDF Print E-mail


This e-mail address is being protected from spambots. You need JavaScript enabled to view it


M.Sc. Molecular biology (Comenius University, Faculty of Natural Sciences, Bratislava, Slovakia)

Project description

Malignant melanoma is one of the most common forms of fatal skin cancer. The annual incidence of this serious disease has increased dramatically over the past few decades. The disease is often characterized by activating mutation BRAFV600E in the BRAF gene. The RAS-RAF-mitogen-activated protein kinase pathways mediate the cellular response to growth signals. Several BRAF inhibitors have been developed to target the BRAFV600E mutation. However, secondary or acquired mutation has been observed after few months of treatment with BRAF inhibitor PLX4032 (vemurafenib). Thatís why a single-target therapy is not effective and multiple targets should be aimed. The chondroitin sulfate proteoglycan 4 (CSPG4) is a cell surface protein highly expressed by melanoma cells and plays an important role in the activation of several signaling pathways important to tumor cell growth, survival, migration, progression. We decided to analyze the effect of combinational treatment of three melanoma cell lines A375, 518A2, M14 on cell migration, proliferation and expression profile under normoxic and hypoxic conditions.


Courses from Network meeting in Basel, March 2014

Courses from Network meeting in Copenhagen, August 2014

Network meetings

Basel,†Switzerland, March 18-19, 2014

Copenhagen, Danmark, August 25-28, 2014

Bremen, Germany, February 23-24, 2015


XXII International Pigment Cell Conference, September 4-7, 2014 Singapore

5th Centrum Retreat, 16. September 2014

Bremen, Germany, 24. February 2015